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Abstract
Failure of elimination of amyloid-b (Ab) from the brain and vasculature appears to be a key factor in the etiology of sporadic
Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA). In addition to age, possession of an apolipoprotein E
(APOE) e4 allele is a strong risk factor for the development of sporadic AD. The present study tested the hypothesis that
possession of the APOE e4 allele is associated with disruption of perivascular drainage of Ab from the brain and with
changes in cerebrovascular basement membrane protein levels. Targeted replacement (TR) mice expressing the human
APOE3 (TRE3) or APOE4 (TRE4) genes and wildtype mice received intracerebral injections of human Ab40. Ab40 aggregated in
peri-arterial drainage pathways in TRE4 mice, but not in TRE3 or wildtype mice. The number of Ab deposits was significantly
higher in the hippocampi of TRE4 mice than in the TRE3 mice, at both 3- and 16-months of age, suggesting that clearance of
Ab was disrupted in the brains of TRE4 mice. Immunocytochemical and Western blot analysis of vascular basement
membrane proteins demonstrated significantly raised levels of collagen IV in 3-month-old TRE4 mice compared with TRE3
and wild type mice. In 16-month-old mice, collagen IV and laminin levels were unchanged between wild type and TRE3
mice, but were lower in TRE4 mice. The results of this study suggest that APOE4 may increase the risk for AD through
disruption and impedance of perivascular drainage of soluble Ab from the brain. This effect may be mediated, in part, by
changes in age-related expression of basement membrane proteins in the cerebral vasculature.
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Introduction
Accumulation of insoluble 39–42 amino acid amyloid-b (Ab)
peptides in the brain parenchyma is one of the pathological
hallmarks of Alzheimer’s disease (AD). The majority of AD
patients will also develop Ab40 accumulation in the walls of
cortical and leptomeningeal arteries as cerebral amyloid angio-
pathy (CAA) [1]. Increasing evidence suggests that CAA
contributes to the pathophysiology of AD, as vascular Ab
deposition is associated with the death of endothelial and smooth
muscle cells, pericytes as well as increased vessel tortuosity and
disturbances in cerebrovascular function [1–4]. Clinically, CAA
correlates with cerebral hypoperfusion, microhemorrhages and
cognitive impairment [5–9].
Although age is the strongest risk factor for the development of
sporadic AD, there is also a robust association between CAA, AD
and possession of the apolipoprotein E (apoE) e4 allele [10,11].
ApoE is the predominant apolipoprotein expressed in the brain
and plays an important role in the transport, uptake and
redistribution of cholesterol [12,13]. Variation in the human
APOE gene sequence results in the presence of three alleles (e2, e3
and e4), which encode the production of three corresponding
protein isoforms (E2, E3 and E4). Individuals expressing one or
two copies of the e4 allele are at higher risk of developing AD, with
an earlier age of onset [14]. Deposition of Ab in capillary walls and
increased severity of CAA are observed in the brains of humans
and transgenic mice expressing human apoE4 [11,15,16].
However, the mechanisms that underlie this susceptibility are
unknown.
Recent evidence supports the hypothesis that CAA is the result
of incomplete clearance of Ab from the brain [17,18]. Multiple
mechanisms mediate Ab removal from the brain, including
enzymatic degradation, uptake by microglia and macrophages,
receptor-mediated transport across the endothelium and drainage
within interstitial fluid (ISF) along cerebrovascular basement
membranes [19,20]. Experimental and histological evidence
suggests that these clearance mechanisms are affected by
expression of the apoE4 isoform. For example, levels of insulin-
degrading enzyme are significantly lower in the brains of apoE4-
positive transgenic mice and humans with AD, compared to those
possessing apoE2 or apoE3 [21,22]. Microglia and macrophages
derived from transgenic mice expressing human apoE4 have
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altered cell morphology, higher production of pro-inflammatory
cytokines and are less efficient at degrading Ab than those from
apoE2 and apoE3 mice [23,24]. In addition, binding of Ab to
apoE has been shown to redirect transport across the blood-brain
barrier (BBB) in an isoform specific manner (apoE4 . apoE3 or
apoE2), towards slower clearance via very low density lipoprotein
receptors [25]. However, little is known about the putative effect of
apoE genotype on the elimination of Ab from the brain along
vascular basement membranes.
Cerebral vascular basement membranes are thin sheets of
highly specialized extracellular matrix that are composed of
laminins, collagen IV, nidogens and heparan sulfate proteoglycans
such as perlecan and agrin [26,27]. Basement membranes regulate
endothelial and smooth muscle cell growth, differentiation and
migration and are proposed to be an important pathway for the
efflux of ISF from the brain [17,26,27]. Previous studies have
demonstrated that solutes injected into the murine brain co-
localize with basement membranes in the walls of capillaries and
arteries [28]. Further, solute diffusion occurs rapidly and is
detected in capillary walls within 5 minutes of injection and within
perivascular macrophages at 30 minutes post-injection [28].
Changes in basement membrane expression and morphology are
observed in the vasculature of the aging and AD brain and result
in the disturbed elimination of solutes from the parenchyma and
the development of CAA [3,29,30]. Furthermore, laminin,
collagen IV, nidogen, agrin and perlecan, can interact directly
with Ab and influence its aggregation [31–34].
There is also evidence to suggest that apoE mediates the
interaction between Ab and basement membrane proteins. In vitro
experiments have shown that laminin binds apoE and inhibits
Ab40 fibril formation induced by apoE4 [35,36]. ApoE and Ab co-
localize in the cerebral vasculature of mouse and AD brains
[37,38] and a significant reduction in the surface area of agrin
immunoreactivity has been reported previously in the brains of
AD individuals homozygous for the APOE4 allele [39]. In
addition, recent findings from transgenic PDAPP mice expressing
human apoE4 have demonstrated elevated levels of soluble Ab
within their cerebral ISF, without increased Ab production [40],
suggesting the possible influence of apoE on the perivascular
drainage of Ab from the brain. Therefore, in the present study, we
tested the hypothesis that the presence of human apoE3 and
apoE4 isoforms differentially affects the level of cerebrovascular
basement membranes and the pattern of perivascular drainage of
Ab from the adult mouse brain. We found that the pattern of Ab40
distribution following injection into the hippocampus was signif-
icantly disrupted in the arterial walls of 3- and 16-month old
TRE4 animals, but not in TRE3 or wildtype mice. Further,
analysis of vascular basement membrane protein levels showed
increased collagen IV levels in 3-month old TRE4 mice compared
with TRE3 and wild type mice. In 16-month-old mice, collagen
IV and laminin levels were unchanged between wild type and
TRE3 mice, but were lower in TRE4 mice. These results suggest
that expression of apoE4 may promote Ab accumulation in AD in
part by modifying the expression of cerebral vascular basement
membrane proteins and disrupting the efficiency of perivascular
drainage of Ab from the brain.
Results
Effect of apoE Genotype on Perivascular Drainage of Ab
To evaluate the effect of apoE isoform on perivascular clearance
of Ab from the parenchyma, 3- and 16-month old wildtype, TRE3
and TRE4 mice were injected into the left hippocampus with non-
fibrillar, oligomeric HiLyte FluorTM 488-labeled human Ab40
(Fig. S1a and b). Fluorescently-labeled Ab peptides have been
used to assess Ab uptake into neurons, microglia and transport
across the BBB, suggesting that fluorophore attachment does not
alter the ability of clearance mechanisms to interact with and
remove Ab from the brain [41–43]. Ab distribution was evaluated
following a ten-minute diffusion period to allow for adequate
perivascular drainage while minimizing Ab clearance across the
BBB or uptake by perivascular macrophages, as previously
demonstrated [25,28]. Similar to the distribution of Ab in human
CAA [17], intracerebrally-injected Ab co-localized with laminin-
positive basement membranes in the tunica adventitia and the
tunica media of leptomeningeal arteries and in the glia limitans
and tunica media of the hippocampal arteries in wildtype and
apoE TR mice (Figs. 1 and 2). In 3-month old wildtype mice, Ab
distributed in a thin, even layer along the entire length of the vessel
wall (Fig. 1a–d). A similar pattern of distribution was noted in the
brains of young TRE3 mice (Fig. 1e–h). The profile of Ab labeling
in young TRE4 mice was mixed, with Ab evenly distributed along
some portions of the blood vessels, and with a patchy, amorphous
appearance in other regions (Fig. 1i–l). In the 16-month old
animals, the distribution of Ab along the vessels of wildtype mice
resembled that in the young mice, albeit with a rougher, thicker
appearance, which corresponded to age-related changes in
laminin morphology (Fig. 2a–d). Likewise, the appearance of Ab
in the aged TRE3 mice was evenly distributed along the length of
the vessel wall (Fig. 2e–h). By contrast, in the 16-month old TRE4
mice, most of the Ab was observed as large deposits that appeared
to have aggregated in the vessel walls (Fig. 2i–l). These Ab
aggregates were identified in vessels throughout the hippocampus
at varying distances from the site of injection, suggesting that their
deposition was not due to fibrillization upon injection. The
number of Ab deposits was significantly higher in the hippocampi
of TRE4 mice than in the TRE3 mice, at both 3- and 16-months
of age (p,0.05, Table 1). No differences were noted in
hippocampal blood vessel density between TRE3 and TRE4 mice
at any age (data not shown).
To determine if the pattern of Ab deposition in the TRE4 mice
was due to binding of human Ab40 to vascular deposits of
endogenous mouse Ab [44], brain tissue sections from aged TRE4
mice were processed for Ab immunoreactivity using an anti-Ab
antibody (clone 4G8) that recognized epitopes of both mouse and
human Ab. The anti-Ab antibody localized predominantly to the
human Ab that had been injected into the ipsilateral hippocampus
(Fig. S1c and d), suggesting that the Ab aggregates were not
precipitated by previously seeded Ab.
To assess the localization of the vascular Ab deposits in the aged
TRE4 mice in more detail, triple labeling immunocytochemistry
was performed using an anti-laminin antibody in combination
with antibodies against a-smooth muscle actin, glut-1, GFAP, Iba-
1 or CD163. No co-localization was noted between the Ab
aggregates and either smooth muscle cells (Fig. 2i–l), endothelial
cells (Fig. 3a–d), astrocytes (Fig. 3e–h), juxtavascular microglia
(Fig. 3i–l) or perivascular macrophages (Fig. 3m–p), indicating that
the observed Ab deposits do not represent intracellular aggregates,
but are localized to the cerebrovascular basement membrane. This
is further supported by the strong similarity between the pattern of
Ab deposition (Fig. 2l and Fig. 3p) and that observed for laminin
staining in TRE4 mice (Fig. S1e and f). Staining for mouse IgG
was negative in wildtype, TRE3 and TRE4 mice of all ages and
was not detected in Ab deposits (data not shown), suggesting that
BBB integrity was not generally compromised or responsible for
Ab accumulation in the TRE4 mice. In addition, double labeling
of tissue sections from aged TRE3 and TRE4 mice for laminin
and apoE, demonstrated co-localization of apoE with the
Perivascular Drainage of Ab in apoE4 Mice
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e41636
basement membranes in blood vessels in both TRE3 and TRE4
mice (Fig. S1g and h). The degree of apoE staining appeared
higher in arteries of TRE4 mice, but did not co-localize
significantly with the Ab deposits observed in these animals
(Fig. S1g and h).
Cerebrovascular Basement Membranes in Young and Old
TRE3 and TRE4 Mice
We have previously found that alterations in perivascular
clearance of solutes from the brain are associated with changes in
basement membrane levels [30]. To determine if apoE genotype
differentially affects basement membrane protein levels, fronto-
parietal cortices from 3- and 16-month old wildtype, TRE3 and
TRE4 mice were assessed for laminin, collagen IV and agrin levels
by Western blotting. In the 3-month old mice, the levels of laminin
were significantly higher in TRE3 and TRE4 mice compared to
aged-matched wildtype mice (Fig. 4a, p,0.01 and p,0.05,
respectively). Significantly more collagen IV was also noted in
young TRE3 and TRE4 mice versus wildtype controls (Fig. 4b,
p,0.01 and p,0.001, respectively). Agrin levels were unaltered
between young wildtype, TRE3 and TRE4 mice (Fig. 4c).
Analysis of brain homogenates from 16-month old animals did
not reveal significant differences in the level of laminin between
wildtype, TRE3 and TRE4 mice, although there was a trend
towards decreased laminin in the TRE4 mice (Fig. 4d). Similarly,
there was a trend towards decreased levels of collagen IV in the
TRE4 animals (Fig. 4e). No significant differences were noted in
the amount of agrin (Fig. 4f) in the brains of 16-month old
wildtype, TRE3 and TRE4 mice. To evaluate the effect of APOE
genotype on changes in basement membrane levels with age, the
ratios of laminin and collagen IV between 3- and 16-months of age
were calculated (Table 2). An age-dependent decrease in laminin
Figure 1. Distribution of human Ab40 within the cerebral vasculature of 3-month old wildtype, TRE3 and TRE4 mice.
Photomicrographs of a hippocampal leptomeningeal artery in a wildtype mouse (a–d), demonstrating the even distribution of intracerebrally-
injected Ab (green, c and d) along laminin-positive (red, a and d) basement membranes of the tunica adventitia and the tunica media (identified by
the presence of a-smooth muscle actin, blue, b and d). Co-localization of laminin, a-smooth muscle actin and Ab is observed as bright pink. In the
TRE3 mice (e–h), Ab (green, g and h) also distributed evenly along the entire length of laminin-positive (red, e and h) basement membranes in the
tunica media of a hippocampal artery (blue, f and h). By contrast, in the TRE4 mice (i–l), Ab (green, k and l) was uniformly distributed along the
basement membrane of the glia limitans (red, i and l), but appeared aggregated (arrow) in the basement membrane within the tunica media of the
hippocampal artery (blue, j and l). Scale bars: a–d= 10 mm; e–h= 25 mm; i–l = 25 mm.
doi:10.1371/journal.pone.0041636.g001
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was noted for both TRE3 and TRE4 mice, with no significant
difference between ratios (TRE3= 0.8260.11 vs.
TRE4= 0.7860.5, p.0.05). Collagen IV levels also decreased
as a function of age in TRE3 and TRE4 mice, but this decrease
was significantly larger in the TRE4 mice (TRE3=0.8960.08 vs.
TRE4= 0.5160.07; p,0.05).
To determine if the observed differences in basement
membrane proteins were focal or generalized, brain tissue sections
from 3- and 16-month old wildtype, TRE3 and TRE4 mice were
assessed by immunocytochemistry for laminin and collagen IV.
Due to technical difficulties in achieving adequate antigen retrieval
for agrin immunocytochemistry, an anti-perlecan antibody was
used as a marker of heparan sulfate proteoglycans. Consistent with
the Western blot data, increased staining intensity for laminin in
the basement membranes of capillaries was noted in both 3-month
old TRE3 and TRE4 mice compared to age-matched wildtype
mice (Fig. 5a–c). More intense labeling of collagen IV was also
observed in the capillaries of young TRE4 mice than in the TRE3
and wildype mice (Fig. 5d–f). No significant differences were noted
in the intensity of perlecan immunoreactivity of capillary basement
membranes between wildtype, TRE3 or TRE4 mice (Fig. 5g–i).
The pattern of expression of glut-l as a general marker for
endothelial cells was comparable between all groups of 3-month
old mice (Fig. 5j–l), suggesting that the observed differences in
laminin and collagen IV levels were not due to changes in capillary
density.
In capillaries of 16-month old mice, the intensity of laminin
immunolabeling was comparable between agedwildtype andTRE3
Figure 2. Distribution of human Ab40 within the cerebrovasculature of 16-month old wildtype, TRE3 and TRE4 mice.
Photomicrographs of a transverse section of a bifurcating leptomeningeal artery in a wildtype mouse (a–d), demonstrating the distribution of
intracerebrally-injected Ab (green, c and d) along laminin-positive (red, a and d) basement membranes in the tunica media (identified by the presence
of a-smooth muscle actin, blue, b and d). Co-localization of laminin, a-smooth muscle actin and Ab is observed as white or bright pink. In the TRE3
mice (e–h), Ab (green, g and h) distributed along the entire length of laminin-positive (red, e and h) basement membranes of the tunica adventitia
and in the tunica media of a hippocampal leptomeningeal artery (blue, f and h). In the TRE4 mice (i–l), most of the Ab (green, k and l) was observed as
large deposits (arrows) in the basement membrane (red, i and l) of hippocampal arteries (blue, j and l). Scale bars = 25 mm.
doi:10.1371/journal.pone.0041636.g002
Table 1. Number of Ab deposits in the hippocampi of 3- and
16-month old TRE3 and TRE4 mice.
3 months 16 months
TRE3 1.560.3 1.260.8
TRE4 2.760.9* 3.960.6*
*p,0.05, TRE3 vs. TRE4.
doi:10.1371/journal.pone.0041636.t001
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mice, but was significantly decreased in the brains of TRE4 mice
(Fig. 6a–c). The staining pattern of collagen IV in the capillaries of
TRE4 mice was patchy, with large portions of the vessels showing
significantly lower intensity of staining, compared to bothTRE3and
wildtype mice (Fig. 6d–f). No differences were noted in the staining
intensity or pattern of perlecan labeling between 16-month-old
wildtype, TRE3 and TRE4 mice (Fig. 6g–i). No variance was noted
in glut-1 immunolabeling between mouse genotypes at this age
(Fig. 6j–l).
Discussion
Possession of the APOE4 allele is one of the strongest risk factors
for the development of sporadic AD and CAA, but the exact
mechanisms that underlie this susceptibility are unknown. We
tested the hypothesis that perivascular drainage of Ab from the
brain is disrupted in the presence of apoE4, in association with
changes in cerebrovascular basement membrane levels. We found
that Ab40 injected into the hippocampi of TRE4 mice accumu-
lated within the basement membranes of blood vessels, beginning
at 3 months of age and became prominent at 16 months. In
addition, levels of laminin and collagen IV were higher in the
brains of TRE4 mice at 3 months of age, but lower than those of
wildtype and TRE3 mice by 16 months of age. These results
suggest that possession of apoE4 changes the levels of basement
membrane proteins in cerebral blood vessels and disrupts the
efficiency of perivascular drainage of Ab from the brain.
A role for apoE4 in the onset and severity of CAA has
previously been suggested in the brains of transgenic mice
expressing human apoE [11,15]. Fryer et al. [15] showed that
breeding of Tg2576 transgenic mice onto a human APOE3/3
background delayed the development of Ab plaques in the
parenchyma and prevented the development of CAA, while those
on an APOE4/4 background had delayed Ab deposition but more
extensive CAA. Recently, Castellano et al. [40] demonstrated that
the half-life and cerebral levels of Ab in the ISF were increased in
both young and old TgPDAPP mice possessing human apoE4,
compared to those expressing apoE2 and apoE3. Similarly, we
Figure 3. Localization of the Ab deposits in the blood vessels of 16-month old TRE4 mice. Double labeling immunocytochemistry was
used to assess the location of Ab (green) aggregates (arrows) with respect to laminin-positive basement membranes (blue) in hippocampal arteries
and glut-1-positive endothelial cells (red, a–d), GFAP-positive astrocytes (red, e–h), Iba-1-positive juxtavascular microglia (red, i–l) and CD163-positive
perivascular macrophages (red, m–p). No co-localization was observed between Ab aggregates and any cell type, suggesting that the Ab deposits do
not represent intracellular aggregates. Inserts represent x63 magnification. Scale bar: a–1 = 50 mm; m–p= 25 mm.
doi:10.1371/journal.pone.0041636.g003
Perivascular Drainage of Ab in apoE4 Mice
PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e41636
Figure 4. Basement membrane protein levels in the brains of 3- and 16-month old wildtype, TRE3 and TRE4 mice. Frontal-parietal
brain homogenates in 3-month old (a–c) and 16-month-old (d–f) TRE3, TRE4 and wildtype controls were analyzed by Western blotting for the levels of
laminin (a, d), collagen IV (b, e) and agrin (c, f). Levels of laminin and collagen IV were significantly higher in the brains of 3-month old, but not 16-
Perivascular Drainage of Ab in apoE4 Mice
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found that perivascular drainage of Ab contained within
hippocampal ISF was disrupted in the brains of 3- and 16-month
old TRE4 mice. These data suggest that the increase in CAA
severity observed in mice and humans possessing apoE4 may be
due in part to its inefficient drainage along cerebrovascular
basement membranes. Moreover, the presence of Ab deposits in
the vasculature of 3-month old TRE4 mice, suggests that the
disruption of perivascular drainage of Ab from the brain occurs
early and is in line with the pre-symptomatic effects of apoE4 on
Ab concentrations, white matter structure and cognition that have
been reported in young transgenic mice and humans [40,45,46].
The mechanisms that underlie the accumulation of vascular Ab
have not been fully elucidated. Ab is degraded by enzymes, such as
neprilysin and insulin-degrading enzyme, and removed from the
brain by uptake by microglia and macrophages and via lipoprotein
receptor-related protein 1 (LRP)-mediated transport across the
endothelium [19,21–24,47–50]. Recent work has demonstrated an
important role for serum response factor and myocardin in
regulating LRP-1 levels in cerebral vascular smooth muscle cells,
which are also involved in Ab clearance [51]. In addition, Ab
secreted into the cerebral interstitial fluid is removed from the
brain by bulk flow along the basement membranes of capillary and
artery walls [17,28,30]. Changes in cerebrovascular basement
membranes, including thickening, reduplication and vacuolization
are observed in the aging brain and may contribute to the etiology
of AD and CAA [3,29]. Further, aggregation of Ab has been
shown to be inhibited in the presence of laminin, collagen IV and
nidogen but accelerated by agrin and perlecan [31–34]. In the
present study, we found that the levels of laminin and collagen IV
were differentially altered between 3- and 16-month old wildtype,
TRE3 and TRE4 mice, while levels of agrin and perlecan were
unchanged. These results suggest that i) replacement of the mouse
apoE gene with the human homolog affects basement membrane
synthesis and/or degradation in the mouse brain and ii) that
APOE genotype regulates the levels of basement membrane
proteins. Moreover, when analyzed across the lifespan, the change
in the levels of collagen IV between 3- and 16-months of age
appeared greater in TRE4 mice compared to TRE3 animals,
suggesting that apoE genotype might also influence the degree to
which basement membrane expression changes during aging.
Previous reports in human AD and TgAPP mice have suggested
a localization of apoE in blood vessels in the brain [37,38], but it is
not clear if apoE specifically associates with the basement
membrane or mediates the perivascular clearance of Ab. We
found that apoE co-localized with laminin in the blood vessels of
both TRE3 and TRE4 mice. Although TRE4 mice express
endogenously lower hippocampal levels of apoE than TRE3 mice
[52], the apoE staining appeared more robust in the vessels of aged
TRE4 vs. TRE3 mice. However, we did not observe a significant
overlap between apoE and deposits of Ab in the vessels of either
TRE3 or TRE4 mice. The present study suggests that impaired
Ab clearance from the brains of TRE4 mice is due predominantly
to alterations in basement membrane proteins. In light of the
increasing importance that apoE genotype appears to play on the
efficacy of AD therapeutics [53] and the vascular related side
effects of therapeutic removal of Ab [54], these data highlight the
importance of addressing apoE-associated changes in the aging
cerebrovasculature in the design and interpretation of new
therapeutics for the treatment strategies of AD and CAA.
Materials and Methods
Animals
Homozygous, male TRE3 and TRE4 mice [55] were main-
tained on a C57BL/6 background and allowed food and water ad
libitum. Experiments were performed using 3–4 and 16–17 month-
old TRE3, TRE4 mice and age-matched C57BL/6 controls. All
experiments were performed in accordance with animal care
guidelines stipulated by the Animal Care and Use Committee at
the University of Southampton. The protocol was approved by the
Home Office under the Animals Scientific Procedures Act 1986
(project license 30/2008) and all efforts were made to minimize
pain and suffering.
Ab Peptide Preparation and Atomic Force Microscopy
(AFM)
HiLyte FluorTM 488-labeled human Ab40 (100 mg, Cambridge
Biosciences, UK) was solubilized in 50 mL 1% NH4OH, vortexed
for 30 seconds and made up to 100 mM with ice-cold sterile PBS.
To determine the aggregation of status of Ab, freshly prepared Ab
or aliquots incubated in PBS for 24 hours at 37uC were evaluated
by AFM. Ab (5 mL) was spotted onto a freshly cleaved mica disc
(Agar Scientific, Stansted, UK) and imaged in air with a digital
multimode Nanoscope III AFM (Veeco, Mannheim, Germany)
operating in tapping mode with uncoated silicon cantilevers (FM-
W, Nanoworld Innovative Technologies, Switzerland, nominal
spring constant 2.8 N/m).
Intracerebral Injections
3- and 16-month old wildtype and apoE TR mice (n = 4/group)
were injected stereotaxically with 0.5 mL ice-cold Ab40 into the left
hippocampus (coordinates from Bregma: AP=22 mm;
ML=1.8 mm and DV=1.6 mm). Injection capillaries were left
in situ for 2 minutes to prevent reflux along the capillary and mice
were sacrificed 10 minutes post-injection to allow for adequate
perivascular drainage while minimizing Ab clearance across the
BBB or via uptake by microglia or macrophages [25,28]. Mice
were intracardially perfused with phosphate buffered saline (PBS,
pH 7.4), followed by 4% paraformaldehyde and brains processed
for double labeling immunocytochemistry.
Double Labeling Immunocytochemistry
Brain sections (20 mm thickness) were incubated overnight with
anti-laminin (1:500, Sigma-Aldrich, Dorset, UK), developed with
AlexaFluor 546-conjugated anti-rabbit (1:200; Invitrogen, Paisley,
UK) and then incubated with anti-a smooth muscle actin (1:500;
Sigma-Aldrich), anti-glucose transporter-1 (glut-1, Sigma-Aldrich,
month old TRE3 and TRE4 mice versus wildtype mice. Agrin levels were unchanged between wildtype, TRE3 and TRE4 mice at either age. Optic
density ratios of protein to GAPDH levels from 3 blots per antibody were analyzed by repeated measures two-way ANOVA with Bonferroni post-hoc
test. Histograms represent mean optic density ratio values 6 S.E.M., *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0041636.g004
Table 2. Percent change in basement membrane levels of
TRE3 and TRE4 mice with age.
Laminin Collagen IV Agrin
TRE3 218.1613.2 210.868.7 +28.166.6
TRE4 222.166.1 248.6613.6* +33.1614.0
*p,0.05, TRE3 vs. TRE4.
doi:10.1371/journal.pone.0041636.t002
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1:500), anti-glial fibrillary acidic protein (GFAP, 1:1000; Dako,
Ely, UK) or anti-apoE (polyclonal against human apoE, 1:250;
Merck, Nottingham, UK). The next day, sections were rinsed in
PBS and developed with the appropriate fluorescently conjugated
secondary antibody (1:200). Antigen retrieval with formic acid or
citrate buffer was performed for double labeling with anti-Ab17224
(clone 4G8, 1:100, Cambridge Biosciences, Cambridge, UK), anti-
Iba-1 (1:500; Wako Chemicals, Eastleigh, UK) or anti-CD163
Figure 5. Levels and morphology of cerebrovascular basement membrane proteins in cortical capillaries of 3-month old wildtype,
TRE3 and TRE4 mice. Brain tissue sections from wildtype (a, d, g, j), TRE3 (b, e, h, k) and TRE4 mice (c, f, i, l) were processed for laminin, collagen IV
and perlecan immunocytochemistry. The staining intensity of both laminin (a–c) and collagen IV (d–f) was higher in TRE3 and TRE4 mice, compared
to wildtype animals. Perlecan levels were constant across genotypes (g–i). No differences were noted in the pattern of glut-l labeling of endothelial
cells between mouse groups (j–l). Scale bars: a–l = 100 mm; m–o=200 mm.
doi:10.1371/journal.pone.0041636.g005
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antibodies (1:200; AbD Serotec, Kidlington, UK). Photomicro-
graphs were captured using a Leica SP5 confocal laser scanning
microscope (Milton Keys, UK) and exported to Photoshop CS
software.
Western Blotting
Wildtype and apoE TR mice (n = 4/group) were perfused
intracardially with PBS. Brain tissues were sonicated in Ripa lysis
buffer [20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA,
0.1% SDS, 1% Igepal, 50 mM NaF, 1 mM NaVO3] containing
a protease inhibitor cocktail (Merck, Nottingham, UK) and
Figure 6. Cerebrovascular basement membrane levels and morphology in cortical capillaries of 16-month old wildtype, TRE3 and
TRE4 mice. Brain tissue sections from wildtype (a, d, g, j), TRE3 (b, e, h, k) and TRE4 mice (c, f, i, l) were processed by immunocytochemistry for
laminin, collagen IV and perlecan. The staining intensity of laminin (a–c) and collagen IV (d–f) was significantly lower in the blood vessels of TRE4 mice
and had a patchy appearance compared to wildtype and TRE3 mice. Perlecan levels remained unchanged across genotypes (g–i), as did the pattern
of glut-l endothelial cell labeling (j–l). Scale bars: a–l = 100 mm; m–o= 200 mm.
doi:10.1371/journal.pone.0041636.g006
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supernatants (15–30 mg) were separated by gel electrophoresis on
3–8% Tris-acetate gels (Invitrogen, Paisley, UK) and transferred
onto a nitrocellulose membrane. Collagen IV samples were
prepared without b-mercaptoethanol or heat. Membranes were
incubated overnight at 4uC with anti-collagen IV (1:500; Abcam,
Cambridge, UK), anti-laminin (1:500, Sigma-Aldrich, Dorset,
UK) or anti-agrin (1:750; Millipore, Watford, UK) antibodies.
Membranes were stripped and reproved with anti-glyceraldehyde-
3-PDH (GAPDH) antibody (1:50,000; Sigma-Aldrich) to ensure
equal protein loading. Immunoblots were quantified by densitom-
etry using Image J software (NIH, Maryland, USA) and calculated
as an optical density ratio of protein levels normalized to GAPDH
levels.
Enzyme-linked Immunocytochemistry
Wildtype and apoE TR mice (n = 4/group) mice were perfused
with 0.1 M PBS followed by 4% paraformaldehyde. Tissue
sections (20 mm thickness) were treated for 2 minutes at 37uC
with pepsin from porcine gastric mucosa (1 mg/mL in 0.2N HCl,
Sigma-Aldrich) and incubated overnight with anti-laminin (1:500),
anti-collagen IV (1:500), anti-perlecan (1:500; Millipore, Watford,
UK) or anti-glut-1 (1:500) antibodies. Sections were washed with
PBS, incubated with anti-rat or anti-rabbit horseradish peroxidase
conjugates (1:400; Vector Labs, Peterborough, UK) and developed
with nickel-enhanced diaminobenzidine as chromogen.
Statistical Analysis
Assessment of perivascular drainage and basement membrane
levels was carried out in the hippocampus and fronto-parietal
cortex, respectively, as representative brain areas that are most
susceptible to the development to murine CAA. Histograms of
western blots were compiled from 3 blots using mean 6 S.E.M.
values and analyzed using repeated measures one-way ANOVA
with Newman-Keuls post-hoc test or one-way Student’s t-test
(significance set at p,0.05). The number of hippocampal blood
vessels containing Ab deposits in a 775 mm6775 mm field (4
fields/mouse) were counted manually and analyzed using
a Student’s t-test (significance set at p,0.05). For quantification
of hippocampal vessel density, micrographs of glut-1 staining were
converted to binary images (4 sections/mouse), evaluated by
densitometry using Image J software and evaluated using a one-
way ANOVA with Newman-Keuls post-hoc test (significance
p,0.05).
Supporting Information
Figure S1 Soluble Aß injected into the hippocampus of
TRE4 mice drains along basement membranes and co-
localizes with apoE. a and b: HiLyte FluorTM 488-labeled
human Ab40 used for intra-hippocampal injections was confirmed
by atomic force microscopy to be oligomeric (a), compared to the
fibrillar Ab that resulted following 24 hrs incubation at 37uC (b). c
and d: Brain tissue sections from 16-month old TRE4 mice were
processed for Ab immunoreactivity using a pan anti-Ab antibody
that recognized both mouse and human Ab. The anti-Ab antibody
localized predominantly to the human Ab (green) that had been
injected into the ipsilateral hippocampus, while little to no mouse
Ab (red) was detected in the vessels in either the ipsi- (c) or
contralateral hippocampus (d). e and f: Laminin staining in the
vessel wall of capillaries in the 16-month old TRE4 mice (arrows)
matched that of the Ab deposits in the same animals. g and h:
Double labeling immunocytochemistry with antibodies against
laminin (blue) and apoE (red) in 16-month old TRE3 (g) and
TRE4 (h) mice injected with human Ab40 (green), showed
localization of apoE with the basement membrane in cortical
and leptomeningeal arteries. Scale bars: a and b= 10 mm; c and
d= 50 mm; e–h= 25 mm.
(TIF)
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